• In early February 2026, Agilent Technologies announced it will showcase next-generation automated workflow innovations, including advanced imaging, AI-driven lab optimization, and compliance-enabling software, at the SLAS2026 International Conference in Boston.
• An interesting aspect of this news is Agilent’s emphasis on open, multi-vendor automation ecosystems that link its instruments with robotics partners like ABB Robotics, HighRes Biosolutions, Biosero, and Unite Labs, potentially deepening its role in integrated laboratory automation.
• Against this backdrop and recent share price weakness, we will examine how Agilent’s AI-powered CrossLab Connect enhancements could influence its broader investment narrative.

We've uncovered the 14 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

What Is Agilent Technologies' Investment Narrative?

To own Agilent today, you have to believe in its position as a picks-and-shovels supplier to regulated life sciences and applied markets, with steady (if not market‑leading) growth, high quality earnings, and a focus on automation and compliance that keeps it embedded in customer workflows. The SLAS2026 showcase of AI‑driven CrossLab Connect tools and multi‑vendor robotics integration fits neatly into that story but is unlikely to change near term catalysts materially by itself, especially against recent share price weakness and modest earnings growth. More immediate drivers still look like execution against FY2026 guidance of US$7.30 billion to US$7.40 billion in revenue, early read‑through from Q1 2026 results on February 25, and how the new CFO and CTO bed down the refreshed operating structure. At the same time, the proposal to declassify the board over three years points to gradually stronger governance and shareholder alignment, which may matter more over the medium term than any single product announcement.

However, one emerging governance risk here is not yet front of mind for many investors. Agilent Technologies' share price has been on the slide but might be up to 11% below fair value. Find out if it's a bargain.

Exploring Other Perspectives

Four Simply Wall St Community fair value estimates for Agilent range from about US$116 to US$170, underlining how far apart individual views can be. Set against the recent board declassification proposal and management transition, that spread gives you several different frameworks to weigh governance change and execution risk against the company’s role in lab automation and regulated workflows, and decide which perspective you find most convincing.

Explore 4 other fair value estimates on Agilent Technologies - why the stock might be worth as much as 31% more than the current price!

Build Your Own Agilent Technologies Narrative

Disagree with this assessment? Create your own narrative in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Agilent Technologies research is our analysis highlighting 4 key rewards that could impact your investment decision.
• Our free Agilent Technologies research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Agilent Technologies' overall financial health at a glance.

Contemplating Other Strategies?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• Find 53 companies with promising cash flow potential yet trading below their fair value.
• AI is about to change healthcare. These 26 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 30 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.